Iowa

Who we are

• April 5, 2022

  Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

• April 5, 2022

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

• April 5, 2022

  REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors

• April 5, 2022

  Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Previous12